Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth
- PMID: 23573305
- PMCID: PMC3606848
Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth
Abstract
Background: Vascular endothelial growth factor (VEGF)-A and VEGF-C are two important molecules involving in tumor development and metastasis via angiogenesis and lymphangiogenesis. However, the combined effect of VEGF-A and VEGF-C on the growth of gastric cancer (GC) is not clear.
Methods: The correlations of VEGF-A and VEGF-C expressions with clinicopathologic parameters and prognosis were evaluated in patients with GC. Furthermore, lentivirus-mediated RNA interfering (RNAi) targeting VEGF-A and/or VEGF-C was employed to silence their expressions in SGC7901 GC cell line. Cell proliferation and apoptosis were measured in vitro. Suppressive effect lentivirus-mediated VEGF-A and/or VEGF-C silencing on GC growth was evaluated in GC bearing mice.
Results: The patients with high expression of both VEGF-A and VEGF-C (A+C+) had larger tumor size, higher peritumoral lymphatic vessel density(P-LVD), microvessel density(MVD), lymphatic vessel invasion (LVI), lymph node(LN) metastasis, and worse prognosis than those with low expression of both VEGF-A and VEGF-C (P<0.05). Lentivirus-mediated RNAi significantly reduced the mRNA and protein expression of VEGF-A and VEGF-C in the SGC7901 cells. The Lenti-miRNA-VEGF-A+VEGF-C significantly inhibited the cell proliferation and tumor growth, compared with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05). In addition, Lenti-miRNA- VEGF-A+VEGF-C markedly lowered the tumor size in vivo in comparison with Lenti-miRNA-VEGF-A or Lenti-miRNA-VEGF-C (P<0.05).
Conclusion: Expressions of both VEGF-A and VEGF-C predict worse prognosis of GC patients. Combined silencing of VEGF-A and VEGF-C markedly suppresses cancer growth than silencing of VEGF-A or VEGF-C. Thus, to inhibit the expressions of VEGF-A and VEGF-C may become a novel strategy for the treatment of GC.
Keywords: Vascular endothelial growth factor-A; gastric cancer; prognosis; tumor growth; vascular endothelial growth factor-C.
Figures






Similar articles
-
RNAi-mediated gene silencing of vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of gastric cancer in vivo in mice.Tumour Biol. 2013 Jun;34(3):1493-501. doi: 10.1007/s13277-013-0674-6. Epub 2013 Mar 10. Tumour Biol. 2013. PMID: 23475632
-
Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications.J Exp Clin Cancer Res. 2011 Jan 28;30(1):14. doi: 10.1186/1756-9966-30-14. J Exp Clin Cancer Res. 2011. PMID: 21272377 Free PMC article.
-
DNA demethylation of vascular endothelial growth factor-C is associated with gene expression and its possible involvement of lymphangiogenesis in gastric cancer.Int J Cancer. 2007 Apr 15;120(8):1689-95. doi: 10.1002/ijc.22433. Int J Cancer. 2007. PMID: 17230534
-
Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy.Br J Cancer. 2003 Aug 4;89(3):426-30. doi: 10.1038/sj.bjc.6601145. Br J Cancer. 2003. PMID: 12888807 Free PMC article. Review.
-
HIF1A protein expression is correlated with clinical features in gastric cancer: an updated systematic review and meta-analysis.Sci Rep. 2024 Jun 14;14(1):13736. doi: 10.1038/s41598-024-63019-6. Sci Rep. 2024. PMID: 38877062 Free PMC article.
Cited by
-
Discussion on the mechanism of Tiaoqi Xiaowei decoction in the treatment of chronic atrophic gastritis based on network pharmacology and molecular docking: An observational study.Medicine (Baltimore). 2024 May 31;103(22):e38224. doi: 10.1097/MD.0000000000038224. Medicine (Baltimore). 2024. PMID: 39259113 Free PMC article.
-
miR‑1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.Oncol Rep. 2018 Aug;40(2):589-598. doi: 10.3892/or.2018.6463. Epub 2018 May 24. Oncol Rep. 2018. PMID: 29845255 Free PMC article.
-
Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer.Exp Ther Med. 2014 Jul;8(1):125-132. doi: 10.3892/etm.2014.1699. Epub 2014 Apr 29. Exp Ther Med. 2014. PMID: 24944610 Free PMC article.
-
A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy.Int J Mol Sci. 2017 Aug 17;18(8):1786. doi: 10.3390/ijms18081786. Int J Mol Sci. 2017. PMID: 28817103 Free PMC article. Review.
-
Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model.Oncotarget. 2015 Jun 20;6(17):15639-51. doi: 10.18632/oncotarget.3712. Oncotarget. 2015. PMID: 25909226 Free PMC article.
References
-
- Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharm Bull. 2011;34:1785–1788. - PubMed
-
- Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K. VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer. 2005;8:155–163. - PubMed
-
- Bjorndahl MA, Cao R, Burton JB, Brakenhielm E, Religa P, Galter D, Wu L, Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2005;65:9261–9268. - PubMed
-
- Shida A, Fujioka S, Ishibashi Y, Kobayashi K, Nimura H, Mitsumori N, Suzuki Y, Kawakami M, Urashima M, Yanaga K. Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg. 2005;29:1600–1607. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous